ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 519

In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage

Ceri Richards1, Carol Hitchon2, Xiaobo Meng3, Irene Smolik4, David Robinson4 and Hani S. El-Gabalawy4, 1Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 2Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 3University of Manitoba, Winnipeg, MB, Canada, 4Arthritis Center, University of Manitoba, Winnipeg, MB, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: complement, Early Rheumatoid Arthritis, pathogenesis, race/ethnicity and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Complement activation, a key component of innate immunity and activator of adaptive immunity has been linked to RA pathogenesis. Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) may cause complement activation.  We examined the association of the terminal complement component C5 and its breakdown product C5a with ACPA in a preclinical Indigenous North American (INA) population at high risk for severe RA.

Methods:  C5, C5a, and ACPA were examined by enzyme-linked immunosorbent assay ELISA, RF by nephlometry, in 267 sera from INA with RA (n=43), first degree relatives (FDR) (ACPA positive n=16; ACPA negative n=64) and FDR who later developed synovitis (FDR-S; n=10).  Samples were spun and stored at -20C.  ACPA positive FDRs samples were matched to one or two ACPA negative FDR samples based on date of sample collection.  Levels were correlated with sample storage duration to assess for in vitro complement activation.  Associations between C5, C5a, ACPA, and subject group were determined using Chi squared, Mann Whitney U tests and Wilcoxon signed ranks tests for paired samples.  Correlations were tested by Spearman correlation.  Multivariable models controlling for time stored, ACPA, RF, visit sequence and sex were generated to determine the independent influence of ACPA on C5 and C5a serum levels.  Data are reported as median (interquartile range (IQR)) and B with 95% confidence limits (CL).

Results: C5a levels increased with increasing time stored (rho=0.69; p<0.0001); C5 levels decreased (rho= -0.33;p=0.002); median (IQR) time stored 6.3(5.5) years).  This presumed in vitro activation was most important for samples stored over 5 years. In FDR samples matched for time stored, C5a and C5 levels were similar between FDR persistently ACPA positive vs  ACPA negative (C5a 17.8 (6.3) vs 17.0 (6.7) ng/ml; p=ns; C5 135.2 (81.7) vs  130.8 (87.5) µg/ml; p=ns).  Comparing all samples from FDRs, C5 levels were higher in ACPA positive vs ACPA negative samples (135.2 (46.6) vs  71.2 (75) µg/ml; p<0.001). Using linear regression to determine predictors of C5 levels in 153 samples from 80 FDR, the presence of ACPA independently predicted higher C5 level (B (CL) 42 (17-71)) after correcting for duration  of time sample stored, visit sequence, sex and RF (titre > 40 U/ml being positive). This association with ACPA was not seen for C5a. In FDR-S (n=10), ACPA titers increased prior to synovitis.  FDR-S had higher C5a levels than FDR (238 (225) vs 133 (362) ng/ml; p<0.0001) an association that was significant after correcting for duration of storage, visit sequence, ACPA, RF and sex (B=95(16-174); p=0.02).

Conclusion: In vitro complement activation may occur with prolonged sample storage and must be considered in any analysis of stored samples. C5 level is independently predicted by ACPA in FDR in an INA prospective cohort suggesting decreased activity of the terminal complement cascade in the presence of ACPA. Those who transitioned to synovitis showed evidence of increased complement activity and prior to onset of synovitis showed expansion of ACPA. ACPA related complement cascade activation in imminent synovitis cannot be confirmed based on this data.


Disclosure: C. Richards, None; C. Hitchon, None; X. Meng, None; I. Smolik, None; D. Robinson, None; H. S. El-Gabalawy, Canadian Institutes of Health research grant, 2.

To cite this abstract in AMA style:

Richards C, Hitchon C, Meng X, Smolik I, Robinson D, El-Gabalawy HS. In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/in-indigenous-north-americans-at-high-risk-for-ra-complement-c5-level-is-associated-with-acpa-positivity-and-c5a-with-transition-to-synovitis-even-after-correcting-for-in-vitro-complement-activation-f/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-indigenous-north-americans-at-high-risk-for-ra-complement-c5-level-is-associated-with-acpa-positivity-and-c5a-with-transition-to-synovitis-even-after-correcting-for-in-vitro-complement-activation-f/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology